NTLA - インテリア・セラピュ―ティクス (Intellia Therapeutics Inc.)

NTLAのニュース

   Oppenheimer Stick to Their Hold Rating for Intellia Therapeutics By Investing.com  2021/05/27 16:05:12 Investing.com
Oppenheimer Stick to Their Hold Rating for Intellia Therapeutics
   Intellia Therapeutics Inc Shares Close the Day 10.1% Higher - Daily Wrap  2021/05/11 22:30:00 Kwhen Finance
Intellia Therapeutics Inc (NTLA) shares closed today 10.1% higher than it did at the end of yesterday. The stock is currently up 23.2% year-to-date, up 279.6% over the past 12 months, and up 186.6% over the past five years. Today, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.5%. Trading Activity Shares traded as high as $68.82 and as low as $56.47 this week.Shares closed 3e+1% below its 52-week high and 3e+2% above its 52-week low.Trading volume this week was 11.0% higher than the 10-day average and 18.9% higher than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.9. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, beats it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -199.8% The company's stock price performance over the past 12 months beats the peer average by -3135.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Leerink Partners Stick to Their Buy Rating for Intellia Therapeutics By Investing.com  2021/03/02 14:48:20 Investing.com
Leerink Partners Stick to Their Buy Rating for Intellia Therapeutics
   Robert W. Baird Stick to Their Hold Rating for Intellia Therapeutics By Investing.com  2021/02/28 14:45:51 Investing.com
Robert W. Baird Stick to Their Hold Rating for Intellia Therapeutics
   FXNEWS24 |Vertex, Intellia Therapeutics: Gene Modifying Shares To Watch | UK Forex Reviews  2021/02/12 11:33:11 FXNews24
Vertex, Intellia Therapeutics: Gene Modifying Shares To Watch | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
   Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO Sells $1,552,255.72 in Stock  2021/02/12 11:27:09 Watchlist News
Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John M. Leonard sold 22,942 shares of the firm’s stock in a transaction that occurred on Friday, February 5th. The shares were sold at an average price of $67.66, for a total value of $1,552,255.72. Following the sale, the chief executive officer now owns 654,803 shares of the company’s stock, […]
   Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Sells $861,675.00 in Stock  2021/02/12 10:43:12 Watchlist News
Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Jose E. Rivera sold 11,489 shares of the stock in a transaction that occurred on Tuesday, February 9th. The stock was sold at an average price of $75.00, for a total value of $861,675.00. Following the completion of the transaction, the executive vice president now directly owns 129,409 shares of […]
   FXNEWS24 |Vertex, Intellia Therapeutics: Gene Modifying Shares To Watch | UK Forex Reviews  2021/02/12 11:33:11 FXNews24
Vertex, Intellia Therapeutics: Gene Modifying Shares To Watch | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
   Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO Sells $1,552,255.72 in Stock  2021/02/12 11:27:09 Watchlist News
Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John M. Leonard sold 22,942 shares of the firm’s stock in a transaction that occurred on Friday, February 5th. The shares were sold at an average price of $67.66, for a total value of $1,552,255.72. Following the sale, the chief executive officer now owns 654,803 shares of the company’s stock, […]
   Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Sells $861,675.00 in Stock  2021/02/12 10:43:12 Watchlist News
Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Jose E. Rivera sold 11,489 shares of the stock in a transaction that occurred on Tuesday, February 9th. The stock was sold at an average price of $75.00, for a total value of $861,675.00. Following the completion of the transaction, the executive vice president now directly owns 129,409 shares of […]
   John M. Leonard Sells 109,889 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock  2021/02/05 09:24:43 Watchlist News
Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John M. Leonard sold 109,889 shares of the firm’s stock in a transaction dated Monday, February 1st. The shares were sold at an average price of $64.00, for a total transaction of $7,032,896.00. Following the completion of the sale, the chief executive officer now owns 575,488 shares of the company’s […]
   Raymond James Stick to Their Buy Rating for Intellia Therapeutics By Investing.com  2021/01/08 16:51:48 Investing.com
Raymond James Stick to Their Buy Rating for Intellia Therapeutics

calendar